Standard Operating Procedure for Handling of Returned Drug Product in API Manufacturing
| Department | API Manufacturing |
|---|---|
| SOP No. | SOP/API/178/2025 |
| Supersedes | SOP/API/178/2022 |
| Page No. | Page 1 of 14 |
| Issue Date | 14/04/2025 |
| Effective Date | 16/04/2025 |
| Review Date | 14/04/2026 |
1. Purpose
To establish a standardized procedure for the receipt, inspection, evaluation, disposition, and documentation of returned drug products in the API manufacturing facility, ensuring traceability and regulatory compliance as per GMP guidelines.
2. Scope
This SOP applies to all finished API batches or intermediate products returned from customers, distributors, or other facilities. It includes procedures for return evaluation,
reprocessing, destruction, and record management.
3. Responsibilities
- Warehouse Staff: Receive returned product and initiate documentation.
- QA Officer/Executive: Conduct visual inspection, initiate investigation, and coordinate evaluation.
- QC Department: Perform required testing on returned samples, if necessary.
- Head – QA: Make final disposition decision (e.g., reprocess, destroy, or release).
- Customer Service: Provide reason for return, handling instructions, and customer communication records.
4. Accountability
The Head of QA is accountable for ensuring that all returned drug products are handled in accordance with applicable regulations, product integrity standards, and company policies.
5. Procedure
5.1 Receipt of Returned Drug Product
- Upon arrival of returned product, Warehouse staff shall:
- Verify transport documentation
- Segregate the product from usable stock
- Label clearly as “Returned Material – Quarantine”
- Initiate Return Receipt Form (Annexure-1)
5.2 Documentation Requirements
- QA shall ensure the following information is collected:
- Product name, batch number, quantity returned
- Reason for return (damage, expiry, quality issue, temperature deviation)
- Customer complaint or communication details
- Transport and storage conditions during return
5.3 Visual and Preliminary Inspection
- QA shall perform visual inspection of returned containers for:
- Seal integrity
- Label condition
- Physical damage
- Cross-contamination risk
- Record observations in Return Evaluation Form (Annexure-2).
5.4 Evaluation and Risk Assessment
- QA, in coordination with QC and Production, shall evaluate:
- Stability concerns due to environmental exposure
- Possibility of contamination or mix-up
- Retention samples comparison (if available)
- Need for reanalysis or reprocessing
- QC may test returned samples for assay, impurities, moisture, and microbial count if required.
5.5 Disposition Decision
- Based on findings, QA Head shall decide whether:
- The product is suitable for reprocessing
- The product may be returned to stock (in rare cases)
- The product must be destroyed
- Record the final disposition decision in Disposition Form (Annexure-3).
5.6 Handling of Approved Returns
- If returned product is suitable for reprocessing:
- Initiate batch reprocessing protocol
- Revise BMR accordingly
- Retest and release via QA as per reprocessing SOP
- All steps must be approved before execution.
5.7 Handling of Rejected Returns
- If product is rejected:
- Label as “To Be Destroyed”
- Transfer to rejection area
- Destroy as per site destruction SOP with QA witness
- Destruction details must be entered in the Destruction Log (Annexure-4).
5.8 Record Keeping and Trending
- All returned product records must be maintained for at least 5 years.
- QA shall compile quarterly return summary reports (Annexure-5) including:
- Number of returns
- Return reasons
- Disposition trends
- Discussed during management review and APQR.
6. Abbreviations
- QA: Quality Assurance
- QC: Quality Control
- BMR: Batch Manufacturing Record
- APQR: Annual Product Quality Review
7. Documents
- Return Receipt Form (Annexure-1)
- Return Evaluation Form (Annexure-2)
- Disposition Form (Annexure-3)
- Destruction Log (Annexure-4)
- Quarterly Return Summary Report (Annexure-5)
8. References
- 21 CFR 211.204 – Returned Drug Products
- ICH Q10 – Pharmaceutical Quality System
- EU GMP Part I – Chapter 8 (Complaints and Product Recall)
9. SOP Version
Version: 2.0
10. Approval Section
| Prepared By | Checked By | Approved By | |
|---|---|---|---|
| Signature | |||
| Date | |||
| Name | |||
| Designation | |||
| Department |
11. Annexures
Annexure-1: Return Receipt Form
| Date | Product | Batch No. | Qty Returned | Customer | Reason |
|---|---|---|---|---|---|
| 12/04/2025 | API-X | AXB2025 | 25 kg | Client A | Seal damage |
Annexure-2: Return Evaluation Form
| Parameter | Observation | Remarks |
|---|---|---|
| Seal Condition | Intact | Acceptable |
| Labeling | Clear | Legible |
| Container Damage | None | OK |
Annexure-3: Disposition Form
| Batch No. | Disposition | QA Decision | Date |
|---|---|---|---|
| AXB2025 | Reprocess | Approved | 13/04/2025 |
Annexure-4: Destruction Log
| Date | Batch No. | Qty Destroyed | Method | Witness |
|---|---|---|---|---|
| 14/04/2025 | AXC2025 | 10 kg | Incineration | QA Officer |
Annexure-5: Quarterly Return Summary Report
| Quarter | Total Returns | Major Reasons | % Reprocessed | % Destroyed |
|---|---|---|---|---|
| Q1 2025 | 4 | Seal leakage, Label smudge | 50% | 50% |
Revision History:
| Revision Date | Revision No. | Details | Reason | Approved By |
|---|---|---|---|---|
| 01/01/2022 | 1.0 | Initial SOP | New document | QA Head |
| 14/04/2025 | 2.0 | Added return summary reporting and destruction log | Process improvement | QA Head |